Cretostimogene grenadenorepvec, an oncolytic immunotherapy, selectively replicates in and lyses cancer cells with Rb-E2F pathway alterations, releasing antigens that initiate antitumor immune ...

For Cohorts A and B, intravesical cretostimogene will be instilled in combination with DDM, an excipient that enhances adenoviral delivery, for six weekly doses during the induction phase, followed by ...

The first 24 patients who received treatment with cretostimogene and were evaluated for high-grade recurrence-free survival and safety were evaluated. Kaplan-Meier estimates at 3- and 9-month ...

Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in ...

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

Follow-up was done according to EAU guidelines. In 27 patients mIR-371 was evaluated preoperatively and correlated with ...

As such, at ESMO 2025, the investigators analyzed patients with or without baseline bone metastases treated with lenvatinib + pembrolizumab versus sunitinib in the CLEAR study with ∼4 years follow-up ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October ...

KLK2 protein is overexpressed in prostate cancer tissue compared to benign prostate tissue and has been associated with stage ...

The study investigators concluded that EV+P demonstrated activity in advanced urothelial carcinoma tumors with histologic ...